OCULAR THERAPEUTIX, INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Ocular Therapeutix, Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q3 2024.
  • Ocular Therapeutix, Inc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$36.5M, a 6972% decline year-over-year.
  • Ocular Therapeutix, Inc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$174M, a 160% decline year-over-year.
  • Ocular Therapeutix, Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$80.7M, a 13.7% decline from 2022.
  • Ocular Therapeutix, Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$71M, a 984% decline from 2021.
  • Ocular Therapeutix, Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$6.55M, a 95.8% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$174M -$36.5M -$36M -6972% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$138M -$43.8M -$23.1M -112% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$115M -$64.8M -$34.5M -114% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$80.7M -$29.2M -$13.7M -88% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 -$67.1M -$516K +$23.7M +97.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$90.7M -$20.7M -$1.92M -10.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$88.8M -$30.3M -$17.8M -142% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$71M -$15.5M -$11.7M -304% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$59.3M -$24.2M -$26.8M -1010% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 -$32.5M -$18.8M -$10.3M -121% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-07
Q1 2022 -$22.2M -$12.5M -$15.7M -502% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-07
Q4 2021 -$6.55M -$3.85M +$81.8M +95.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-11
Q3 2021 -$88.3M $2.66M +$14.6M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$103M -$8.48M +$28.1M +76.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$131M $3.12M +$24.6M Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$156M -$85.6M -$59.6M -229% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 -$96M -$11.9M +$6.83M +36.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$103M -$36.6M -$12.1M -49.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$90.8M -$21.5M -$4.39M -25.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$86.4M -$26M -$8.62M -49.5% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-12
Q3 2019 -$77.8M -$18.8M -$3.77M -25.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$74M -$24.5M -$10.6M -77.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-05
Q1 2019 -$63.3M -$17.1M -$3.36M -24.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-05
Q4 2018 -$60M -$17.4M -$4.3M -32.8% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$55.7M -$15M +$557K +3.58% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$56.2M -$13.8M +$4.89M +26.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$61.1M -$13.8M +$2.26M +14.1% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$63.4M -$13.1M -$280K -2.18% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$63.1M -$15.6M -$5.97M -62.2% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$57.1M -$18.7M -$7.25M -63.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$49.9M -$16M -$5.18M -47.8% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$44.7M -$12.8M -$2.19M -20.5% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 -$42.5M -$9.6M +$1.93M +16.7% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$44.4M -$11.4M -$1.44M -14.3% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$43M -$10.8M -$3.26M -43% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
Q4 2015 -$39.7M -$10.6M -$2.68M -33.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-10
Q3 2015 -$37.1M -$11.5M -$4.23M -58% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-10
Q2 2015 -$32.8M -$10M -$3.62M -56.6% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-10
Q1 2015 -$29.2M -$7.58M -$570K -8.13% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-10
Q4 2014 -$28.6M -$7.95M -$4.45M -127% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-10
Q3 2014 -$24.2M -$7.29M -$3.77M -107% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-10
Q2 2014 -$20.4M -$6.39M -$3.3M -107% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-10
Q1 2014 -$17.1M -$7.01M -$3.81M -119% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-10
Q4 2013 -$13.3M -$3.51M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-20
Q3 2013 -$3.52M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-20
Q2 2013 -$3.09M Apr 1, 2013 Jun 30, 2013 10-K 2015-03-20
Q1 2013 -$3.2M Jan 1, 2013 Mar 31, 2013 10-K 2015-03-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.